MRVI Q2 2023 Earnings — Maravai LifeSciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

MRVIMaravai LifeSciences Holdings, Inc.

$999M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$69M-71.6% YoY

Gross Profit

$26M37.2% margin

Operating Income

-$12M-16.9% margin

Net Income

-$7M-9.5% margin

EPS (Diluted)

$-0.05

QoQ Revenue Growth

-12.8%

Cash Flow

Operating Cash Flow

$19M

Free Cash Flow

-$6M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$2.3B

Total Liabilities

$1.4B

Stockholders' Equity

$521M

Cash & Equivalents

$580M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$69M	$243M	-71.6%
Gross Profit	$26M	$205M	-87.5%
Operating Income	-$12M	$181M	-106.4%
Net Income	-$7M	$71M	-109.2%

Revenue Segments

Nucleic Acid Production Segment

$53M77%

Biologics Safety Testing Segment

$16M23%